血脂康对急性缺血性脑卒中并高脂血症患者超敏C-反应蛋白变化的影响

目的探讨血脂康对急性缺血性脑卒中并高脂血症患者超敏C-反应蛋白变化的影响。方法将46例患者随机分为辛伐他汀组20例,血脂康组26例,测定调脂治疗前后神经功能缺损评分、血脂和超敏C-反应蛋白等指标。结果治疗前后两组神经功能缺损评分和总胆固醇均降低、TC/HDL-C比值升高,差异有统计学意义(P<0.05),两组间比较无显著性差异(P>0.05);超敏C-反应蛋白水平和甘油三脂均降低,差异有统计学意义(P<0.05),两组间比较有显著性差异(P<0.05)。结论血脂康能治疗急性缺血性脑卒中患者,在调脂同时,可减轻炎性损伤。

Objective To study the effects of Xuezhikang on the change of plasma hs-crp level in patients with hyperlipidemia and acute ischemic stroke. Methods The 46 patients were divided into Xuezhikang group of 26 patients and Simvastatin group of 20 patients at random. The clinical neurologic functional default scoring （CNFDS）, the serum lipids （TC, TG, LDL-C, HDL-C） and the plasma hs-crp level were measured before and after therapy in all cases. Results The CNFDS and the TC both decreased and the TC/HDL-C increased after the therapy（P〈0.05）, there was no statistics difference between two groups（P〉0.05）; the plasma hs-crp level and the TG both decreased after the therapy（P〈0.05）,and the effects in Xuezhikang group was better than that in Simvastatin group（P〈0.05）. Conclusion While adjustment the serum lipids, Xuezhikang can mitigate the inflammation damnification in treatment of the patients with hyperlipoidemia and acute ischemic stroke.